AtriCure, Inc. (ATRC) Position Boosted by Schwab Charles Investment Management Inc.
Schwab Charles Investment Management Inc. raised its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 1.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 161,031 shares of the medical device company’s stock after buying an additional 1,789 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.47% of AtriCure worth $3,906,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also bought and sold shares of the stock. Sei Investments Co. grew its position in AtriCure by 75.5% during the second quarter. Sei Investments Co. now owns 6,933 shares of the medical device company’s stock worth $168,000 after buying an additional 2,983 shares in the last quarter. Essex Investment Management Co. LLC grew its position in AtriCure by 19.8% during the second quarter. Essex Investment Management Co. LLC now owns 142,774 shares of the medical device company’s stock worth $3,462,000 after buying an additional 23,585 shares in the last quarter. US Bancorp DE grew its position in AtriCure by 152.1% during the second quarter. US Bancorp DE now owns 4,202 shares of the medical device company’s stock worth $102,000 after buying an additional 2,535 shares in the last quarter. Bank of America Corp DE grew its position in AtriCure by 42.0% during the first quarter. Bank of America Corp DE now owns 26,389 shares of the medical device company’s stock worth $505,000 after buying an additional 7,809 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in AtriCure during the first quarter worth about $760,000. Institutional investors and hedge funds own 82.11% of the company’s stock.
Several research firms recently commented on ATRC. Needham & Company LLC restated a “buy” rating and set a $26.00 target price (up from $25.00) on shares of AtriCure in a research report on Friday, July 28th. Zacks Investment Research cut AtriCure from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. BidaskClub cut AtriCure from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Canaccord Genuity restated a “buy” rating and set a $28.00 target price on shares of AtriCure in a research report on Monday, October 9th. Finally, Stifel Nicolaus restated a “buy” rating and set a $25.00 target price on shares of AtriCure in a research report on Sunday, July 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $25.83.
In other news, Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total value of $224,000.00. Following the sale, the director now directly owns 29,967 shares of the company’s stock, valued at $671,260.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.00% of the company’s stock.
AtriCure, Inc. (NASDAQ ATRC) opened at 22.46 on Wednesday. AtriCure, Inc. has a 12-month low of $14.78 and a 12-month high of $25.18. The stock’s market capitalization is $771.14 million. The stock has a 50 day moving average price of $21.85 and a 200-day moving average price of $21.95.
AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 27th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.05. AtriCure had a negative return on equity of 19.56% and a negative net margin of 19.56%. The firm had revenue of $45.23 million for the quarter, compared to analysts’ expectations of $44.15 million. During the same period in the previous year, the firm posted ($0.26) earnings per share. The business’s revenue was up 14.0% compared to the same quarter last year. On average, equities analysts anticipate that AtriCure, Inc. will post ($0.95) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “AtriCure, Inc. (ATRC) Position Boosted by Schwab Charles Investment Management Inc.” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/10/18/atricure-inc-atrc-position-boosted-by-schwab-charles-investment-management-inc.html.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC).
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.